GenWay and Beckman form biomarker discovery pact :
This article was originally published in Clinica
Executive Summary
GenWay Biotech is to provide Beckman Coulter with access to its method for enhancing the detection of biomarkers and drug targets, under an exclusive licensing deal formed between both parties. The method, IgY technology, selectively partitions the 12 most abundant proteins - up to 96% of the protein mass - from human serum or plasma. Because highly abundant plasma proteins are the main cause of assay noise, and may interfere with the detection of important biomarkers and drug targets, this technology could significantly facilitate the discovery of novel proteins, explained San Diego, California-based GenWay.
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.